UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043335
Receipt number R000049372
Scientific Title Borderline Personality Disorder in Japan -A Qualitative Research on Experience and Perceptions of Individuals Who Receive Counselling and or Treatment
Date of disclosure of the study information 2021/02/26
Last modified on 2022/12/15 18:55:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Borderline Personality Disorder in Japan -A Qualitative Research on Experience and Perceptions of Individuals Who Receive Counselling and or Treatment

Acronym

Borderline Personality Disorder Experiences and Perceptions in Japan

Scientific Title

Borderline Personality Disorder in Japan -A Qualitative Research on Experience and Perceptions of Individuals Who Receive Counselling and or Treatment

Scientific Title:Acronym

Borderline Personality Disorder Experiences and Perceptions in Japan

Region

Japan


Condition

Condition

Borderline personality disorder

Classification by specialty

Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Describe burdens of Borderline Personality Disorder and the impact on life based on experiences and perceptions (symptoms, thoughts, emotions, behaviours) of individuals who have difficulties and receive counselling and/or treatment, and identify their needs and priorities for treatment. Moreover, investigate whether there are any differences in the perspectives of individuals concerned and carers.

Basic objectives2

Others

Basic objectives -Others

Not applicable

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Information on experiences and perceptions about borderline personality disorder

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

-An individual receiving counselling for difficulty in controlling his/her emotions
-An individual with suspected borderline personality disorder (at the counsellor's judgement)
-An individual perceived as having difficulty in controlling his/her emotions (at the counsellor's judgement)
-His/her counsellor also gives his/her own consent to participate in the study as a study subject
-20+ years of age

Key exclusion criteria

-Not eligible at the counsellor's discretion

Target sample size

4


Research contact person

Name of lead principal investigator

1st name Nobutaka
Middle name
Last name Yagi

Organization

Nippon Boehringer Ingelheim Co., Ltd.

Division name

Medicine Division

Zip code

141-6017

Address

2-1-1 Osaki, Shinagawa-ku, Tokyo, Japan

TEL

03-6417-2043

Email

nobutaka.yagi@boehringer-ingelheim.com


Public contact

Name of contact person

1st name Nobutaka
Middle name
Last name Yagi

Organization

Nippon Boehringer Ingelheim Co., Ltd.

Division name

Medicine Division

Zip code

141-6017

Address

2-1-1 Osaki, Shinagawa-ku, Tokyo, Japan

TEL

03-6417-2043

Homepage URL


Email

nobutaka.yagi@boehringer-ingelheim.com


Sponsor or person

Institute

Nippon Boehringer Ingelheim Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Nippon Boehringer Ingelheim Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Corporation Kyoso-kai AMC Nishi-Ume da Clinic Ethics Review Committee

Address

Maruit Nishi-Umeda Building 3F, 3-3-45 Umed a, Kita-ku, Osaka-shi, Osaka, Japan

Tel

06-4797-5660

Email

morikawa@amc-clinic.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 02 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

4

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 01 Month 26 Day

Date of IRB

2021 Year 01 Month 28 Day

Anticipated trial start date

2021 Year 02 Month 27 Day

Last follow-up date

2021 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Non-interventional, cohort study


Management information

Registered date

2021 Year 02 Month 16 Day

Last modified on

2022 Year 12 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049372


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name